Cisplatin - supply shortage
Ongoing
cisplatin
ShortageHuman
Shortage information
Cisplatin is used alone or with other medicines to treat various cancers that are either advanced or metastatic (have spread to other parts of the body).
The company Accord, one of the main providers of cisplatin in the EU, is experiencing capacity issues at one of its manufacturing sites in India. While these issues are being resolved, the company cannot produce sufficient cisplatin to meet the demand. This has resulted in a shortage which is expected to last until 2025. There are no safety or quality concerns with product on the market.
The shortage affects or may affect all Member States where the product is marketed. For up-to-date information about the status of a medicine shortage in a particular EU/EEA Member State, consult the national shortage register or contact the national competent authority.
EMA’s SPOC working party is closely monitoring the supply situation and engaging with the marketing authorisation holders of alternative cisplatin medicines to increase their supplies. It is also engaging with Accord to provide regulatory support.
The SPOC working party is responsible for monitoring and reporting events that could affect the supply of medicines in the EU.
- Manufacturing capacity issues are affecting the supply of cisplatin medicines in some European countries.
- Before starting treatment, healthcare professionals should ensure that sufficient supplies are available to complete the treatment.
- In case of supply shortages, healthcare professionals should consider alternative treatment options for their patients. For additional information consult your country’s shortage register or contact your national competent authority
- Healthcare professionals can also contact relevant healthcare professional organisations for further information.
Manufacturing capacity issues are affecting the supply of cisplatin medicines in some European countries.
Your doctor will check that there are sufficient supplies available before starting treatment.
In case cisplatin medicines become unavailable, your doctor will discuss possible alternatives with you.
If you have any questions, speak to your doctor or pharmacist.
For additional information, consult your country’s shortage register or contact your national competent authority.
You may also contact relevant patients’ organisations for further information or support:
Key facts
- Medicines affected
- Cisplatin
- Supply shortage status
- Ongoing
- International non-proprietary name (INN) or common name
- cisplatin
- Therapeutic area (MESH)
- Cancer
- Neoplasms
- Pharmaceutical forms affected
- Solution for injection
- Availability of alternatives
- Yes
Key dates
- First published